WeVote
Log In

Bill

RA

Bill

A 5383

Requires unrestricted Medicaid coverage for ovulation enhancing drugs and medical services related to administering such drugs for certain beneficiaries experiencing infertility.

2024-2025 Regular Session Introduced by Reginald Atkins and 6 co-sponsors

New Jersey bill mandates Medicaid coverage of ovulation-enhancing drugs and fertility services for infertile beneficiaries, expanding access but increasing state healthcare costs.

Received in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee
#health #medicaid
0
WeVote Research Nonpartisan
Bill Summary · A 5383

Legislative bill overview

Bill A 5383 mandates that New Jersey's Medicaid program provide unrestricted coverage for ovulation-enhancing drugs and related medical services needed to administer them for eligible beneficiaries experiencing infertility. The bill passed the Assembly overwhelmingly (76-2-2) and is currently under review in the Senate Health Committee. This represents an expansion of fertility treatment access to a population that typically faces financial barriers to reproductive services.

Why is this important

Infertility affects approximately 12% of women of reproductive age, and fertility treatments can cost $12,000-$15,000 per cycle without insurance coverage. By mandating Medicaid coverage, the bill addresses healthcare equity by enabling low-income individuals to access treatments previously available mainly to those with private insurance or substantial savings. This could significantly increase fertility treatment access while also potentially increasing state healthcare expenditures.

Potential points of contention

  • Fiscal impact: Medicaid coverage expansion typically increases state spending; fiscal estimates and long-term cost projections will be crucial for Senate deliberations
  • Scope of "unrestricted" coverage: The bill's language on unlimited cycles, age limits, or other parameters could face debate regarding sustainability and medical necessity standards
  • Religious and philosophical objections: Some stakeholders may raise concerns about government-funded fertility treatments on ideological grounds, though this appears less prominent in current legislative discussions

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.